Optimization of Antiplatelet Therapy in ACS: Lessons from the Experts
Release Date: July 6, 2020
Expiration Date: July 6, 2021
This activity is intended for cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, primary care physicians, technologists and nurses who manage thrombotic risks across diverse patient populations.
Statement of Need
This activity is designed to address the following core and team competencies: Patient Care and Medical Knowledge.
Upon completion of this activity learners should be able to:
- Discuss the latest guidelines for antiplatelet therapy in ACS.
- Describe the impact of oral antiplatelet therapy on Cardiovascular Mortality in ACS.
- Outline the latest efficacy and safety data of antiplatelet therapies for patients undergoing PCI.
This activity is designed to address the following core and team competencies: Patient Care and Medical Knowledge,
This activity is supported by an educational grant from AstraZeneca
[Cine'-Med] is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Cine-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
The [Cine'-Med] designates this enduring material for a maximum of [1.5] AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
In accordance with the appropriate accrediting bodies, all planners, teachers, and authors with control over activity content are required to disclose to the provider any relevant financial relationships (those held by the planner or significant other, currently or within the last 12 months) with commercial interests. Accredited providers are required to provide this information to learners before the start of an activity.
The following is a list of the faculty, along with any information they have disclosed regarding their relevant financial relationships.
Deepak Bhatt, MD – Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis
Rajesh Dave, MD – Speaker’s Bureau: AstraZeneca
C. Michael Gibson, MD – Research Support / Consulting Funds: Janssen, Johnson & Johnson; Research Support (Baim Institute): Bristol –Myers Squibb; Consulting Funds: Bayer
Bryan Kluck, DO – Speaker’s Bureau: Chiesi
Roxana Mehran, MD – Research Grants: Abbott, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb, CERC, Chiesi, Concept Medical, CSL Bering, DSI, Medtronic, Novartis, OrbusNeich; Consultant: Abbott, Boston Scientific, Janssen, Medscape/WebMD, Medtelligence, Roivant Scieneces, Sanofi, Siemens Medical Solutions,
Samir Mehta, MD – Research Grants: AstraZeneca, Boston Scientific
Tullio Palmerini, MD – No relevant financial relationship(s) to disclose.
All information contained within this activity is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site. No single reference or service can take the place of medical training, education and experience. This web site does not define a standard of care, nor is it intended to dictate an exclusive course of management. This information should not substitute for a visit or consultation with a health care provider.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.